Executive Summary

Patient-Derived Xenograft (PDX) models are fundamental for generating decision-driving oncology data. However, their translational value is entirely dependent on the operational rigour used to manage them. Inconsistent passaging, genetic drift, or logistical failures can invalidate study outcomes and delay programs. Franklin Biolabs provides bespoke PDX colony management, ensuring the biological integrity of these complex models from initial implantation through large-scale efficacy studies. We combine GxP-compliant operations within our >100,000 sq ft facility with a deep understanding of tumour biology to preserve the fidelity of your unique patient-derived assets.

Preserving Tumour Heterogeneity in Preclinical Studies

The core challenge in oncology research is translating preclinical efficacy into clinical success. PDX models, which retain the cellular and structural heterogeneity of the original human tumour, offer a superior predictive platform. Yet, this biological complexity demands a highly specialized management approach.

• Preventing Model Drift: Each PDX model possesses unique growth kinetics. A one-size-fits-all approach to expansion leads to selective pressures and genetic drift, compromising the model’s representation of the patient’s disease.

• Ensuring Scalability: Progressing a therapeutic candidate requires scaling a PDX colony from a few initial hosts to potentially hundreds for pivotal efficacy and safety studies. This requires precise logistical planning and significant infrastructure.

• Maintaining Data Integrity: The chain of custody and molecular identity of each model must be impeccably maintained. Any deviation introduces variables that can confound study results and undermine regulatory submissions.

The Value of Patient-Derived Systems

The utility of using patient-derived tissues to create more predictive in vivo platforms is well-documented. A study developing a xenograft model from patient hepatocytes successfully recapitulated human familial hypercholesterolaemia, enabling the validation of an AAV9-based gene therapy that restored normal function (PMID: 26081744). This highlights how a well-characterized, patient-derived system provides a direct translational bridge for evaluating novel therapeutic constructs before human trials.

Conversely, the limitations of preclinical models in predicting complex human immune reactions underscore the need for model fidelity. A tragic outcome in an early gene therapy trial was linked to a severe systemic inflammatory response not fully anticipated from prior studies (PMID: 14567964). While not a PDX study, this event reinforces the principle that the more biologically relevant the model, the more reliable the data. For PDX models, this means preserving the specific tumour microenvironment that may influence therapeutic response.

Watch the full-length video ‘DIVERSIFYING THE VALUE CHAIN’

Operational Excellence for UK Oncology Programmes

Franklin Biolabs provides the infrastructure and expertise to manage large, diverse PDX portfolios for UK-based sponsors. Our approach is built to support the typical 18-24 month timeline from late-stage preclinical work to a successful IND submission. This commitment to operational excellence has contributed to a 100% IND application success rate for programmes supported since 2019. (The Franklin Biolabs brand launched in 2024). Our services provide the robust, reproducible data required for regulatory confidence.